Lisanti Capital Growth’s Axsome Therapeutics AXSM Stock Holding History

Lisanti Capital Growth’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.1M	Sell	20,825 -1,250	-6%	-$271K	1.12%	36
2026 Q1	$3.73M	Buy	+22,075	New	+$3.81M	0.94%	47
2025 Q2	–	Sell	-33,280	Closed	-$3.88M	–	109
2025 Q1	$3.88M	Buy	+33,280	New	+$3.79M	1.15%	33
2023 Q3	–	Sell	-33,325	Closed	-$2.39M	–	121
2023 Q2	$2.39M	Buy	+33,325	New	+$2.46M	0.33%	102

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Lisanti Capital Growth's AXSM Position: Q2 2026 in Review

Lisanti Capital Growth reduced its Axsome Therapeutics (AXSM) stake by 5.7% in Q2 2026, selling an estimated $271K and leaving 20,825 shares worth $5.1M. The position accounts for 1.12% of the portfolio, ranked #36.

Lisanti Capital Growth first reported a position in AXSM in Q2 2023 and has held it in 4 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Lisanti Capital Growth held 20,825 shares of Axsome Therapeutics worth $5.1M as of Q2 2026.
Lisanti Capital Growth sold 1,250 Axsome Therapeutics shares in Q2 2026, an estimated $271K.
Axsome Therapeutics made up 1.12% of Lisanti Capital Growth's portfolio in Q2 2026, its #36 holding.
Lisanti Capital Growth first reported a position in Axsome Therapeutics in Q2 2023 and has held it in 4 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Lisanti Capital Growth's 13F filing for Q2 2026, filed 10 Aug 2026.